Clinical Trials Logo

MDS clinical trials

View clinical trials related to MDS.

Filter by:

NCT ID: NCT04644016 Recruiting - AML Clinical Trials

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

Start date: November 20, 2020
Phase: Phase 2
Study type: Interventional

This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.

NCT ID: NCT04638309 Terminated - Clinical trials for Myelodysplastic Syndromes

APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)

Start date: September 20, 2021
Phase: Phase 1
Study type: Interventional

Phase 1 study evaluating the safety and efficacy of APR-548 in combination with Azacitidine for the treatment of TP53-Mutant Myelodysplastic Syndromes.

NCT ID: NCT04623944 Active, not recruiting - MDS Clinical Trials

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Start date: September 21, 2020
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high risk relapsed/refractory MDS.

NCT ID: NCT04573686 Not yet recruiting - MDS Clinical Trials

Prognostic Value of Serum Erythropoietin Level,Ferritin Level and Fibrinogen in Adult Low Risk MDS

Start date: January 1, 2021
Phase:
Study type: Observational

1. assessment of the penefit of erythropoietin administration in decreasing the frequency of blood transfusion in adult low risk MDS 2. assessement of the clinical significance of the relationship between hyperfibrinogenemia and the prognosis of patients with low risk MDS 3. assessement of the association between serum ferritin levels and patient _reported aspects and symptomes

NCT ID: NCT04511975 Suspended - MDS Clinical Trials

A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS

Start date: August 24, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, phase 1b study to evaluate the safety, tolerability and preliminary efficacy of IBI188 in combination with Azacitidine in newly diagnosed higher risk MDS patients.

NCT ID: NCT04473911 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Haplo Peripheral Blood Sct In GVHD Prevention

Start date: August 14, 2020
Phase: Phase 1
Study type: Interventional

This research study is studying the RGI-2001 for preventing Graft-vs-Host Disease (GVHD) in people with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative disorders (MPN), chronic myelomonocytic leukemic (CMML), chemosensitive hodgkin lymphoma (HL), or Non-Hodgkin lymphoma (NHL).who will have a blood stem cell transplantation. - GVHD is a condition in which cells from the donor's tissue attack the organs. - RGI-2001 is an investigational treatment

NCT ID: NCT04443751 Completed - AML Clinical Trials

A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Start date: September 10, 2020
Phase: Phase 1
Study type: Interventional

This study will assess the safety and preliminary efficacy of escalating doses of SHR-1702 monotherapy in relapsed/refractory AML and intermediate-high risk MDS

NCT ID: NCT04358393 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

Start date: December 4, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a two Part study in patients with relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or high risk myelodysplastic syndrome (MDS) that will initially evaluate the safety and tolerability of APG-115 as a single agent in Part 1, followed by a combination of APG-115 + 5-azacitidine (5-AZA) in Part 2.

NCT ID: NCT04187105 Recruiting - Acute Leukemia Clinical Trials

BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

Start date: January 27, 2020
Phase: Phase 2
Study type: Interventional

Pre-transplant conditioning will include targeted total marrow irradiation (TMI) at a dose of 6Gy. Graft-versus-host disease prophylaxis will include cyclophosphamide 50 mg/kg on Day +3 and 4 along with tacrolimus and mycophenolate mofetil

NCT ID: NCT04110925 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With Myelodysplasia

Start date: September 2019
Phase: N/A
Study type: Interventional

This study evaluates the relationship between myelodysplastic syndromes (MDS) and cardiovascular disease. MDS patients will be evaluated for the presence of mutations and whether they are associated with an increased risk of heart disease (CVD) and inflammation compared to healthy adults. Patients without symptoms of CVD will receive CT scans to assess for hidden disease and if that is related to their mutations.